Selventa, Janssen Partner on Immunological Diseases | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Selventa today announced a research agreement with Janssen Research & Development in immunological diseases.

The deal includes the development of disease models to shed information about disease-relevant mechanisms and to identify new drug discovery opportunities, Selventa said. Aside from saying the deal is multi-year the company did not disclose the terms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.